ASX:IMMPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Immutep Ltd
$0.052
$0.002 (3.70%)
Day Range
$0.051 – $0.054
52 Week Range
$0.028 – $0.470
Volume
1.70M
Avg Volume (10D)
5.54M
Market Cap
$76.63M
Price Chart
OHLC · volume · moving averages
$0.052-$0.333 (-86.49%)over 6M
Hi$0.400Lo$0.028Avg Vol27.7M
Price-sensitive newsVolumePrev close · 52W rangeDrag the handles below to zoom
Market Statistics
Today's trading range
Open
$0.053
Previous Close
$0.054
Day High
$0.054
Day Low
$0.051
52 Week High
$0.470
52 Week Low
$0.028
Valuation
Fundamental multiples
Market Cap
76.63M
Shares Outstanding
1.47B
Price to Book
0.80
Trading Activity
Volume & order book
Volume
1.70M
Value Traded
88.95K
Bid
$0.051 × 667,226
Ask
$0.053 × 135,000
Performance
Returns across timeframes
1 Day
1.89%
5 Day
1.89%
13 Week
-3.57%
52 Week
-78.40%
YTD
-86.99%
Technical Indicators
Momentum & moving averages
RSI (14)
52.94
50-Day SMA
$0.051
200-Day SMA
$0.186
— From the desk
Latest News
Biotechnology
Immutep Granted FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
Immutep wins FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, boosting exclusivity and regulatory support as TACTI-004 winds down.
Hot Topics
Weekly Wrap: Shares fall another 2.6% for the week as conflict worsens
ASX 200 slides 2.6% this week to 8,617 as Iran-Israel conflict lifts oil above $100; NST and SYR plunge, while EOS soars on a Middle East contract.
Biotechnology
Immutep Discontinues TACTI-004 Phase III Trial Due to Futility
Immutep halts TACTI-004 Phase III in first-line NSCLC due to futility; shares resume trading as cash runway extends beyond Q2 CY2027.
Biotechnology
Immutep TACTI-004 NSCLC Trial At 50% Enrolment, Paving Way for Futility Analysis
Immutep (ASX: IMM) has achieved a significant milestone, announcing 50% patient enrolment in its global Phase III TACTI-004 trial for first-line non-small ce